Display options
Cite
Chatziralli I, Vlachodimitropoulou A, Daoula C, et al. Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. Int J Retina Vitreous. 2018;4:33doi: 10.1186/s40942-018-0137-8.
Chatziralli, I., Vlachodimitropoulou, A., Daoula, C., Vrettou, C., Galani, E., Theodossiadis, G., & Theodossiadis, P. (2018). Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. International journal of retina and vitreous, 433. https://doi.org/10.1186/s40942-018-0137-8
Chatziralli, Irini, et al. "Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature." International journal of retina and vitreous vol. 4 (2018): 33. doi: https://doi.org/10.1186/s40942-018-0137-8
Chatziralli I, Vlachodimitropoulou A, Daoula C, Vrettou C, Galani E, Theodossiadis G, Theodossiadis P. Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. Int J Retina Vitreous. 2018 Sep 19;4:33. doi: 10.1186/s40942-018-0137-8. eCollection 2018. PMID: 30250750; PMCID: PMC6145103.
Copy Download .nbib Format: NLM
Share it on

Int J Retina Vitreous. 2018 Sep 19;4:33. doi: 10.1186/s40942-018-0137-8. eCollection 2018.

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature.

International journal of retina and vitreous

Irini Chatziralli, Aikaterini Vlachodimitropoulou, Chrysoula Daoula, Christina Vrettou, Eleni Galani, George Theodossiadis, Panagiotis Theodossiadis

Affiliations

  1. 12nd Department of Ophthalmology, National and Kapodistrian University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342 Athens, Greece.
  2. 2Medical School, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 30250750 PMCID: PMC6145103 DOI: 10.1186/s40942-018-0137-8

Abstract

PURPOSE: The purpose of this review is to examine the role of eplerenone in the treatment of central serous chorioretinopathy (CSCR).

METHODS: A comprehensive search of the PubMed database has been conducted regarding eplerenone for CSCR, while studies using spironolactone were excluded. Articles and book chapters cited in the reference lists of articles obtained by this method were reviewed and included when considered appropriate, while the retrieved articles were filtered manually to exclude duplicates.

RESULTS: Oral eplerenone at a dose of 25-50 mg/day has been found to be effective and well-tolerated for the treatment of chronic CSCR. The published studies have shown significant improvement in visual acuity and decrease or total absorption of subretinal fluid in patients with CSCR treated with oral eplerenone. However, it should be noted that the majority of studies were retrospective with limited number of patients and short follow-up. On the other hand, patients presenting widespread retinal pigment epithelium changes are less likely to benefit from eplerenone treatment, which may argue for an earlier intervention.

CONCLUSIONS: CSCR is a challenging disease to understand and treat, since its pathogenesis remains elusive and multifactorial. Pharmacologic approaches, like eplerenone, are intriguing, as they target several pathophysiological pathways and may lead to visual acuity improvement and more rapid recovery.

Keywords: Central serous retinopathy; Chronic; Eplerenone; Mileralocorticoid

References

  1. Ophthalmology. 2015 Mar;122(3):562-70 - PubMed
  2. Eur J Ophthalmol. 2016 Aug 4;26(5):479-84 - PubMed
  3. Retina. 2018 May;38(5):962-969 - PubMed
  4. Retina. 2013 Nov-Dec;33(10):2096-102 - PubMed
  5. FASEB J. 2010 Sep;24(9):3405-15 - PubMed
  6. Drug Metab Dispos. 2003 Nov;31(11):1448-55 - PubMed
  7. Acta Ophthalmol. 2014 Sep;92(6):e488-90 - PubMed
  8. Ophthalmology. 2014 May;121(5):1067-72 - PubMed
  9. Clin Exp Ophthalmol. 2013 Mar;41(2):187-200 - PubMed
  10. Int Ophthalmol. 2016 Oct 18;:null - PubMed
  11. Ophthalmology. 2008 Jan;115(1):169-73 - PubMed
  12. Curr Eye Res. 2017 Jul;42(7):1069-1073 - PubMed
  13. Semin Ophthalmol. 2017;32(1):36-42 - PubMed
  14. Ann Acad Med Singapore. 2006 Feb;35(2):77-9 - PubMed
  15. Surv Ophthalmol. 2013 Mar-Apr;58(2):103-26 - PubMed
  16. Ophthalmic Res. 2016;56(1):17-22 - PubMed
  17. Clin Ophthalmol. 2015 Aug 11;9:1449-56 - PubMed
  18. Ophthalmic Surg Lasers Imaging Retina. 2015 Apr;46(4):439-44 - PubMed
  19. Transl Vis Sci Technol. 2016 Mar 4;5(2):2 - PubMed
  20. Acta Ophthalmol. 2008 Mar;86(2):126-45 - PubMed
  21. Retina. 2016 Mar;36(3):611-8 - PubMed
  22. Retina. 2012 Feb;32 Suppl 1:709 - PubMed
  23. J Fr Ophtalmol. 2016 Jun;39(6):535-42 - PubMed
  24. Cochrane Database Syst Rev. 2015 Dec 22;(12):CD011841 - PubMed
  25. Graefes Arch Clin Exp Ophthalmol. 1988;226(6):548-52 - PubMed
  26. Retina. 2016 Feb;36(2):402-7 - PubMed
  27. J Med Life. 2016 Jan-Mar;9(1):92-94 - PubMed
  28. Clin Exp Ophthalmol. 2013 Mar;41(2):201-14 - PubMed
  29. Am J Physiol Renal Physiol. 2001 Feb;280(2):F181-92 - PubMed
  30. Eur Rev Med Pharmacol Sci. 2013 May;17(10):1369-73 - PubMed
  31. Am J Ophthalmol. 1996 Jan;121(1):26-34 - PubMed
  32. J Clin Invest. 2012 Jul;122(7):2672-9 - PubMed
  33. Curr Opin Neurol. 2016 Feb;29(1):49-54 - PubMed
  34. Eye (Lond). 2010 Dec;24(12):1743-56 - PubMed
  35. Int J Ophthalmol. 2015 Apr 18;8(2):310-4 - PubMed
  36. Prog Retin Eye Res. 2015 Sep;48:82-118 - PubMed
  37. Acta Ophthalmol. 2017 Nov;95(7):e610-e618 - PubMed
  38. Graefes Arch Clin Exp Ophthalmol. 2016 Nov;254(11):2151-2157 - PubMed
  39. Retina. 2017 Jun;37(6):1084-1091 - PubMed

Publication Types